Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
Vivani Medical (NASDAQ: VANI) has announced its participation in a virtual fireside chat hosted by H.C. Wainwright & Company on April 24, 2025, at 10 a.m. Eastern Time. The presentation will feature CEO Adam Mendelsohn, Ph.D., and CMO Lisa Porter, M.D., who will discuss the company's LIBERATE-1 clinical trial.
The discussion will focus on NPM-115, Vivani's innovative miniature, twice-yearly GLP-1 (exenatide) implant being developed for chronic weight management. The company is currently conducting LIBERATE-1 as a first-in-human study, with topline data expected in mid-year 2025.
Vivani specializes in developing miniature, ultra long-acting drug implants, with a portfolio focusing on once or twice-yearly GLP-1 implants for both chronic weight management and type 2 diabetes treatment.
Vivani Medical (NASDAQ: VANI) ha annunciato la sua partecipazione a un incontro virtuale informale organizzato da H.C. Wainwright & Company il 24 aprile 2025 alle 10:00 ora della costa est degli Stati Uniti. La presentazione vedrà la partecipazione del CEO Adam Mendelsohn, Ph.D., e della CMO Lisa Porter, M.D., che parleranno dello studio clinico LIBERATE-1 dell'azienda.
La discussione sarà incentrata su NPM-115, l'innovativo impianto miniaturizzato di GLP-1 (exenatide) di Vivani, somministrato due volte l'anno e sviluppato per la gestione cronica del peso. Attualmente, l'azienda sta conducendo LIBERATE-1 come studio di prima somministrazione nell'uomo, con dati preliminari attesi a metà 2025.
Vivani è specializzata nello sviluppo di impianti farmaceutici miniaturizzati e a lunga durata d'azione, con un portafoglio focalizzato su impianti di GLP-1 da somministrare una o due volte l'anno, destinati sia alla gestione cronica del peso sia al trattamento del diabete di tipo 2.
Vivani Medical (NASDAQ: VANI) ha anunciado su participación en una charla virtual organizada por H.C. Wainwright & Company el 24 de abril de 2025 a las 10 a.m., hora del Este. La presentación contará con la participación del CEO Adam Mendelsohn, Ph.D., y la CMO Lisa Porter, M.D., quienes hablarán sobre el ensayo clínico LIBERATE-1 de la compañía.
La conversación se centrará en NPM-115, el innovador implante miniaturizado de GLP-1 (exenatida) de Vivani, de administración semestral, desarrollado para el manejo crónico del peso. Actualmente, la empresa está llevando a cabo LIBERATE-1 como un estudio de primera administración en humanos, con datos preliminares esperados para mediados de 2025.
Vivani se especializa en el desarrollo de implantes farmacéuticos miniaturizados y de acción ultralarga, con un portafolio enfocado en implantes de GLP-1 administrados una o dos veces al año, tanto para el manejo crónico del peso como para el tratamiento de la diabetes tipo 2.
Vivani Medical (NASDAQ: VANI)는 2025년 4월 24일 동부 표준시 오전 10시에 H.C. Wainwright & Company가 주최하는 가상 화상 토론회에 참여한다고 발표했습니다. 이번 발표에는 CEO Adam Mendelsohn 박사와 CMO Lisa Porter 박사가 참석하여 회사의 LIBERATE-1 임상시험에 대해 논의할 예정입니다.
토론은 만성 체중 관리를 위해 개발 중인 Vivani의 혁신적인 소형 반기형 GLP-1(엑세나타이드) 임플란트인 NPM-115에 초점을 맞출 것입니다. 회사는 현재 LIBERATE-1을 최초 인체 대상 연구로 진행 중이며, 2025년 중반에 주요 결과가 발표될 예정입니다.
Vivani는 초소형 장기 지속형 약물 임플란트 개발을 전문으로 하며, 만성 체중 관리와 제2형 당뇨병 치료를 위한 연 1~2회 투여 GLP-1 임플란트에 중점을 둔 포트폴리오를 보유하고 있습니다.
Vivani Medical (NASDAQ : VANI) a annoncé sa participation à une discussion virtuelle organisée par H.C. Wainwright & Company le 24 avril 2025 à 10h00, heure de l'Est. La présentation mettra en vedette le PDG Adam Mendelsohn, Ph.D., et la directrice médicale Lisa Porter, M.D., qui discuteront de l'essai clinique LIBERATE-1 de l'entreprise.
La discussion portera sur NPM-115, l'implant innovant miniaturisé de GLP-1 (exénatide) de Vivani, administré deux fois par an et développé pour la gestion chronique du poids. La société mène actuellement LIBERATE-1 en tant qu'étude de première administration chez l'humain, avec des données préliminaires attendues à la mi-2025.
Vivani est spécialisée dans le développement d'implants médicamenteux miniaturisés à action ultra-longue, avec un portefeuille axé sur des implants GLP-1 administrés une ou deux fois par an, destinés à la gestion chronique du poids et au traitement du diabète de type 2.
Vivani Medical (NASDAQ: VANI) hat seine Teilnahme an einem virtuellen Gespräch im Rahmen eines Fireside Chats angekündigt, der von H.C. Wainwright & Company am 24. April 2025 um 10 Uhr Eastern Time veranstaltet wird. Die Präsentation wird vom CEO Adam Mendelsohn, Ph.D., und der CMO Lisa Porter, M.D., gehalten, die die klinische Studie LIBERATE-1 des Unternehmens vorstellen werden.
Die Diskussion wird sich auf NPM-115 konzentrieren, Vivanis innovativen, miniaturisierten GLP-1 (Exenatid) Implantat, das zweimal jährlich zur chronischen Gewichtsregulierung verabreicht wird. Das Unternehmen führt derzeit LIBERATE-1 als Erst-in-Mensch-Studie durch, wobei die wichtigsten Ergebnisse Mitte 2025 erwartet werden.
Vivani spezialisiert sich auf die Entwicklung von miniaturisierten, langwirksamen Arzneimittelimplantaten mit einem Portfolio, das auf einmal- oder zweimal jährlich verabreichte GLP-1-Implantate für die chronische Gewichtsverwaltung und die Behandlung von Typ-2-Diabetes ausgerichtet ist.
- None.
- None.
Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes
Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company’s LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025
ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company.
As part of the presentation, Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D., will discuss Vivani’s LIBERATE-1 clinical trial. LIBERATE-1 is a first-in-human study of NPM-115, the Company’s miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management. Vivani anticipates topline data for LIBERATE-1 in mid-year 2025.
Details for viewing the fireside chat are as follows:
| Date: | Thursday, April 24, 2025 |
| Time: | 10 a.m. Eastern Time |
| Weblink: | https://journey.ct.events/view/8202e32e-0026-417c-8e44-10a1503a831c |
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal platform, Vivani develops therapeutic implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight individuals designed for once or twice-yearly administration. Vivani’s emerging pipeline also includes NPM-119, which refers to the Company’s six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a semaglutide implant for the treatment of type 2 diabetes is also under consideration. These NanoPortal implants are designed to provide patients with the opportunity to experience the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications.
Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, NPM-119, and Vivani’s technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 31, 2025, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462
Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com
(646) 866-4012
FAQ
When will Vivani Medical (VANI) release LIBERATE-1 trial results?
What is Vivani Medical's NPM-115 implant being developed for?
When is Vivani Medical's (VANI) upcoming fireside chat with H.C. Wainwright?
What types of drug implants is Vivani Medical (VANI) developing?
What is the LIBERATE-1 trial studying?
